share_log

Comera Life Sciences Announces Publication Of Study Reinforcing Caffeine's Viscosity Reducing Capabilities

Comera Life Sciences Announces Publication Of Study Reinforcing Caffeine's Viscosity Reducing Capabilities

Comera Life Sciences 宣佈發表一項旨在增強咖啡因降粘能力的研究
Benzinga ·  2023/08/16 20:15

Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies

發表在《藥學雜誌》上的數據支持進一步開發咖啡因作爲單克隆抗體皮下配方的降粘劑

WOBURN, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced the peer-reviewed publication of preclinical data in the Journal of Pharmaceutical Sciences, which provide further evidence of caffeine's viscosity reducing capabilities and support further development of caffeine as a viscosity reducing agent for subcutaneous (SQ) formulations of monoclonal antibodies.

馬薩諸塞州沃本,2023年8月16日(GLOBE NEWSWIRE)——開發新一代生物藥物以改善患者獲得機會、安全性和便利性的生命科學公司Comera Life Sciences Holdings, Inc.(納斯達克股票代碼:CMRA)今天宣佈在《藥物科學雜誌》上發表經過同行評審的臨床前數據,這些數據進一步證明了咖啡因的降粘能力,並支持咖啡因作爲降粘劑的進一步發展用於單克隆抗體皮下(SQ)製劑的藥劑。

These studies aimed to assess the pharmacokinetic (PK) characteristics of caffeine and its influence on the PK behavior of a representative monoclonal antibody (mAb) ipilimumab. The outcomes show rapid SQ absorption and elimination of caffeine, regardless of whether it was administered alone or in conjunction with the monoclonal antibody. Notably, caffeine exhibited no impact on the PK profiles of ipilimumab with SQ administration. Moreover, when caffeine was injected SQ at various dosage levels, no irritation or adverse effects were observed at the injection site.

這些研究旨在評估咖啡因的藥代動力學 (PK) 特徵及其對代表性單克隆抗體 (mAb) ipilimumab 的 PK 行爲的影響。結果表明,無論是單獨給藥還是與單克隆抗體聯合給藥,咖啡因都能快速吸收和消除。值得注意的是,咖啡因對SQ給藥的ipilimumab的PK譜沒有影響。此外,當以不同劑量水平注射SQ咖啡因時,注射部位未觀察到刺激或不良反應。

"This study is an important validation of caffeine's potential to address critical viscosity challenges in developing subcutaneous biologics," said Robert Mahoney, Ph.D., Chief Scientific Officer of Comera. "The results further support the rapid dissociation of caffeine upon subcutaneous injection and that caffeine does not affect pharmacokinetic profiles of the model monoclonal antibody, both of which are critical features of a successful subcutaneous formulation."

Comera首席科學官羅伯特·馬奧尼博士說:“這項研究是對咖啡因在開發皮下生物製劑時應對關鍵粘度挑戰的潛力的重要驗證。”“這些結果進一步支持皮下注射時咖啡因的快速解離,而且咖啡因不會影響模型單克隆抗體的藥代動力學特徵,這兩者都是成功的皮下配方的關鍵特徵。”

"Comera continues to innovate on the delivery of biologic medicines and this publication reflects our extensive expertise in solving some of the most challenging problems in protein engineering," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. "These insights bring us closer to delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines. We look forward to continuing the development of caffeine as a viscosity reducing agent for subcutaneous monoclonal antibody formulations, while also embarking on the expansion of our computational modeling tools to potentially include cutting-edge AI capabilities."

Comera董事長兼首席執行官傑弗裏·哈克曼說:“Comera繼續在生物藥物的交付方面進行創新,這份出版物反映了我們在解決蛋白質工程領域一些最具挑戰性的問題方面的廣泛專業知識。”“這些見解使我們更接近於提供變革性的解決方案,這些解決方案有可能徹底改變我們使用基本藥物的方式。我們期待繼續開發咖啡因作爲皮下單克隆抗體配方的降粘劑,同時還着手擴展我們的計算建模工具,使其有可能包括尖端的人工智能功能。”

The publication titled, "Preclinical Pharmacokinetic Study on Caffeine as an Excipient for Monoclonal Antibody Formulations," is available online here.

這份名爲 “關於咖啡因作爲單克隆抗體配方賦形劑的臨床前藥代動力學研究” 的出版物可在此處在線獲取。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論